#ACR21 Ab#1658 - Autoimmune Risks in Relatives of RA pts. 1st degree relatives have risk of: ▶️ AI thyroid (OR 1.3) ▶️ Celiac (1.5) ▶️ SLE (1.3) ▶️ IBD - no ⬆️ risk ⭐️1st, 2nd, 3rd degree relativ: ⬆️ risk of RA ⭐️2nd degree: ⬆️ risk SLE https://t.co/ATHdemoF45 @Rheumnow #ACRbest https://t.co/JcuZmg9L8E

GLORIA RCT: 400+ pts. Low dose Pred in RA >65yo on top of other treatments 2yrs. Authors conclude benefit/risk balance in favour of GCs 🧐 2 thoughts: 1️⃣ CV risk linked to GCs ⬆️ over time and cumulative dose: Follow up= short! 2️⃣ Small # for CV events #ACR21 #Abst 1678 @RheumNow https://t.co/QECJR68ZJu

Dr Deike on prevalence and incidence of PsA in Germany. Prevalence 5-6/1000. Incidence 30-40/100000. Marked age variations that don't really make sense for prevalence. Abstr#1785 #ACR21 @RheumNow https://t.co/uW0ruW2Jda

What is the likelihood of developing an #autoimmunedisease in first-degree relatives of pts with #RA? Genealogical & phenotypic data suggests lower threshold for screening for autoimmune thyroiditis, #coeliac & #SLE in FDRs. Abs#1658 #ACR21 @RheumNow https://t.co/PdSZ05elsf https://t.co/AkIXDkWCM8

#ACR21 Ab#L02 - #COVID19 vax in rheumatic pts: ❌No ⬆️ in disease activity scores post-vaccination ❌No serious adverse event ▶️Vax response 88% in RA, 78% in SLE, 87% other rheum diseases after 2 shots vs 100% controls ⭐️RTX and MMF ⬇️ responses @Rheumnow https://t.co/BChhmW0jpy https://t.co/2q8IKRoYqW

Dr Hebing on s/c vs oral methotrexate. erythrocyte methotrexate polyglutamates significantly higher with s/c administration. s/c consistently seems to be the better option, better efficacy, less side effects. Abstr#1695 #ACR21 @RheumNow https://t.co/kLGr6pVnxQ

Can we predict which PsO pts will develop PsA? Machine learning and phenotyping of blood immune cell subsets identified an immune profile to discriminate PsO from PsA. Abs#1774 #ACR21 @RheumNow https://t.co/PERx86jjkJ https://t.co/oEpbMZ0nnK

Congrats to Dr. Debaditya Roy, Dr. Chinenye Osuorji and Dr. Vaneet Sandhu on the leaderboard for engaged learning during #ACR21 @rheumnow My points are pathetic compared to theirs and the top 10 https://t.co/yYppc029DM

#ACR21 Ab#L03: B cell depletors and #COVID19 vax: ⭐️B cell count <40 around vax had lower response to vax, than 40+ B-cell, independent of RTX or BEL ▶️ Timing of vax around B cell return can improve response @Rheumnow https://t.co/1B7Bnb1QQu https://t.co/bKnfw6gD8O

#ACR21 #Abstr1491 What’s new in skin #lupus aetiology? Paired skin & blood using scRNA-seq: 💠Nonlesional skin in CLE/SLE is IFN-I-riched 💠Lupus-enriched CD16+ DCs undergo robust IFN education in the skin & gained pro-inflammatory phenotypes @RheumNow https://t.co/70zrC4T7SB https://t.co/75HjvGmNTa

In this study by Prof MAringer et al, majority of #lupus pts enrolled in TULIP 1/2 met the the EULAR/ACR 2019 #SLE criteria 🦋Of few pts not meeting new criteria, most were ANA- w/detectable anti-dsDNA/Smith Ab Better outcomes for criteria+ in TULIP1/2? @RheumNow #ACR21 abs1733 https://t.co/XpfMZQLGUv

Dr Coras on "ITIS" anti-inflammatory diet in RA. Improves fatigue after 2 weeks. Fatigue response dissociated from disease activity response. Open label, but promising. Fatigue remains one of our biggest challenges in RA. Abstr#1699 #ACR21 @RheumNow @ElenaNikiUK https://t.co/tBMqmWAy8m